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1. Introduction 
Toxoplasma gondii was first identified more than 100 years ago in the tissues of birds and 
mammals. In 1908 Nicolle and Manceoux described it for the first time in the gundi 
(Ctenodactylus gundi), a North African rodent, in tachyzoite forms.  At the same time, 
Splendore in Brazil, identified the parasite in rabbit tissues. Due to its bow-like shape 
(Greek: Toxo = Arc) the genus was named Toxoplasma. However, only in the 1970’s was the 
complete life cycle known and the parasite recognized as a coccidian parasite (member of 
the phylum Apicomplexa). It is ubiquitous throughout the world and estimated to infect 
approximately half of the world's population. It is characterized by a polarized cell structure 
and two unique apical secretory organelles called micronemes and rhoptries. 
Toxoplasma has a complex life cycle consisting of a sexual cycle in its feline definitive hosts 
and an asexual cycle in its intermediate hosts. The latter, including humans, can be infected 
by ingestion of oocysts shed in cat feces. Unlike most other Apicomplexan parasites, 
Toxoplasma can be transmitted between intermediate hosts by either vertical (via placenta) or 
horizontal (carnivorism) transmission. 
Toxoplasma parasite is found in intermediate hosts in two interconvertable stages: 
bradyzoites and tachyzoites. Bradyzoites, a dormant form, are slow-growing, transmissible 
and encysted. Infections with bradyzoite-containing cysts occur upon ingestion of 
undercooked meat. The wall of these cysts is digested inside the host stomach and the 
released bradyzoites, which are resistant to gastric peptidases,  subsequently invade the 
small intestine. There, they convert into tachyzoites, the rapidly growing, disease-causing 
form that can infect most nucleated cells, replicate inside a parasitophorous vacuole, egress, 
and then infect neighboring cells. These tachyzoites activate a potent host immune response 
that eliminates most of the parasites. Some tachyzoites, however, escape destruction and 
convert back into bradyzoites. In the absence of an adequate immune response, tachyzoites 
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will grow unabated and cause tissue destruction, which can be severe and even fatal. 
However, the inflammatory immune response induced by tachyzoites can cause immune-
mediated tissue destruction. Therefore, a subtle balance between inducing and evading the 
immune response is crucial for Toxoplasma to establish a chronic infection. 
The success of Toxoplasma as a widespread pathogen is due to the ease in which it can be 
transmitted between intermediate hosts. Humans do not play a major role in 
transmission; consequently, pathogenesis in humans is the indirect result of adaptations 
to infection in other hosts and treatment of human infections is unlikely to lead to the 
spread of drug resistance.  
Once inside a host, the parasite develops powerful tools to modulate its host cell and 
develop into a chronic infection that can evade the host's immune system as well as all 
known anti-toxoplasmatic drugs. The ability of the parasite to replicate within a host cell, 
evade immune responses and undergo bradyzoite development requires the parasite to 
effectively modulate its host. 
Toxoplasmosis remains a major health concern in pregnancy, where it causes severe birth 
defects or miscarriage, and in immunocompromised hosts. Thus, new toxoplasmosis control 
strategies are needed. The development of effective human and veterinary vaccines against 
toxoplasmosis is a relevant goal for Public Health (Gazzinelli et al. 1996; Pifer and 
Yarovinsky 2011). Even if new therapeutic drugs, with less hypersensitivity and toxicity- 
related events, are developed, not only for acute T. gondii infection but also for the currently 
untreatable latent bradyzoite form of the parasite, a prophylactic vaccine against the disease 
would still be the best option from the financial, epidemiological, and social points of view. 
A vaccine would decrease the enormous  costs of diagnosis/treatment, the premature loss of 
lives, the extensive rates of dissemination as well as the social impact of the disease. One 
major fact that suggests the possibility of vaccination against toxoplasmosis is that primary 
infection with the T. gondii parasite elicits protective immunity against re-infection in most 
individuals. 
2. Mechanisms of protective immunity against toxoplasmosis 
Immune responses during the early stages of T. gondii infection are characterized by 
activation of innate mechanisms mediated by macrophages and dendritic cells (DC) 
(Gazzinelli et al. 1996; Pifer and Yarovinsky 2011). These cells are activated in mice (not yet 
known how in humans) after parasite internalization, by engagement of endosomal toll-like 
receptor 11 (and probably others) with tachyzoite products, which drives subsequent 
production of interleukin-12 (IL-12) and tumor necrosis factor alpha (TNF-α). In turn, IL-12 
activates natural killer (NK) cells (Denkers et al. 1993) to secrete gamma interferon (IFN-γ) 
(Gazzinelli et al. 1994), which then acts as stimulus for T-cell activation and, in synergy with 
TNF-α, mediates killing of tachyzoites by macrophages through enhanced production of 
free oxygen radicals and nitric oxide (NO). 
Acquired immunity against T. gondii develops afterward, and is characterized by strong 
CD4+ and CD8+ T cell activity (Gazzinelli et al. 1992). The cytokine IFN-γ continues to be 
central in resistance to the parasite during the successive acute and chronic stages of 
infection, driving the differentiation of CD4+ T lymphocytes specific for parasite antigens to 
a helper T cell type (Th1) cytokine profile. More important, the newly generated CD8+ T 
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cells become crucial to control parasite replication, not only by serving as additional sources 
of IFN-but also by developing cytotoxic activity against infected cells, eliminating parasite 
factories and thus preventing reactivation of infection (Denkers et al. 1993; Denkers and 
Gazzinelli 1998; Bhopale 2003).  Whether B cells also play a role in protection against this 
parasite is not clear, but studies have generated indirect evidences that IgG antibodies may 
be important for protection (Kang et al. 2000). B cell-deficient mice have shown increased 
susceptibility to brain inflammatory pathology in chronic infections with the parasite, 
despite presenting similar levels of serum and tissue pro-inflammatory cytokines, such as 
IFN-γ. Furthermore, adoptive transfer of polyclonal anti- T. gondii IgG antibodies to these 
mice prevented both pathology and mortality. 
3. Major toxoplasma vaccines and candidates studied to date 
To reproduce what the immune system does naturally to protect hosts against T. gondii 
infection (and re-infection), researchers have attempted several strategies for vaccination. 
These include the use of whole parasites (attenuated in different ways), soluble parasite 
antigens, recombinant purified proteins (subunit vaccines) or recombinant live vectors that 
express heterologous antigen(s) within host organisms (figure 1). Currently, some of these 
tools are also being used in combination, as part of prime-boost immunization protocols. 
Below is a review of current’s state of the art of most of these technologies. 
3.1 Whole-parasite attenuated vaccines 
Sporulated oocysts (sporozoite-containing cysts) from the environment or tissue cysts 
(bradyzoite-containing cysts) from infected animals are the two major sources of infection 
with T. gondii (figure 2). However, vaccine candidates that include sporozoites or sporozoite 
antigens have traditionally been less studied because of the ease of access to bradyzoites and 
tachyzoites, e.g. using animal brain cysts or acutely infected animal peritoneal lavage/cell 
cultures, respectively. As a result, the first T. gondii whole-parasite experimental vaccines 
were mainly based on attenuated tachyzoites/bradyzoites, in particular those generated 
by inactivation or irradiation. Inactive parasites were used for immunization of 
experimental animals from 1956 (Cutchins and Warren 1956) to 1972 (Krahenbuhl et al. 
1972) with not much success. In contrast, gamma-irradiated T. gondii tachyzoites were 
successfully tested as experimental vaccines in 1975 (Seah and Hucal 1975), in part after 
taking the idea from the pioneering irradiated-sporozoite malaria vaccines, which were 
initially tested in the 1960s and 70s (Nussenzweig et al. 1967; Gwadz et al. 1979). In the 
1975 report, all animals inoculated with highly irradiated T. gondii parasites survived, 
were free of tissue cysts and were solidly protected against a subsequent rechallenge. 
Later, a few reports (Dubey et al. 1996; Omata et al. 1996; Dubey et al. 1998) have also used 
irradiated sporozoites (under the form of sporulated oocysts) to vaccinate mice, cats and 
pigs against toxoplasmosis, but in contrast to tachyzoites, results were not very 
encouraging, though some protection was also observed. 
Other attempts to induce protection against toxoplasmosis with whole-parasite vaccines 
included the use of live attenuated parasites (tachyzoites) such as the S-48, the cps1-1, the 
temperature-sensitive TS-4, the MIC1-3 knock-out or the non-replicative Δrps13 strains 
(McLeod et al. 1988; Hakim et al. 1991; Buxton 1993; Gigley et al. 2009; Lu et al. 2009; Hutson  
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Fig. 1. Potential advantages (+) and concerns (-) of the major vaccination strategies used to 
immunize hosts against T. gondii infection. Abbreviations: STAg, Soluble Tachyzoite 









Fig. 2. Major T. gondii antigens identified to date in the different stages of the parasite´s life 
cycle and major routes of parasite transmission. Thin black arrow = horizontal transmission 
via oocysts; thick black arrow = horizontal transmission via tissue cysts; dotted arrows = 
vertical transmission via tachyzoites. Abbreviations: SAG, surface antigen; ROP, rhoptry 
protein; GRA, dense granules; MIC, microneme protein; SRS, SAG-related sequences; BSR, 
bradyzoite-specific recombinant; MAG, matrix antigen; LDH, lactate dehydrogenase; ENO, 
enolase; TgERP0, T. gondii embryogenesis-related protein. 
et al. 2010; Mevelec et al. 2010). The only vaccine commercialized for veterinary purposes, 
Ovilis®Toxovax (Intervet/Schering-Plough Animal Health, UK), based on the incomplete 
parasite S-48 strain (not able to generate either tissue cysts or oocysts), began to be marketed 
in New Zealand and the United Kingdom in 1988 to control miscarriages provoked by T. 
gondii in sheep. Reduction in fetal loss and in formation of cysts in the meat used for 
consumption has been reported. This vaccine seems to reduce infection in sheep, which in 
free-range grazing are constantly exposed to oocyst contamination. 
Interestingly, up to date, the most recent and technologically advanced recombinant vaccine 
formulations have reached, at best, the same levels of protective immunity induced by 
whole-parasite vaccines. Three main reasons may be responsible for that difference: (i) true 
protective antigens (or more plausibly antigen combinations) of the parasite have not yet 
been identified, (ii) while the whole organism and the recombinant vaccines contain the 
same antigenic sequences, the process by which the recombinant products are generated 
result in the loss of crucial features that are key for protein’s immunogenicity (Crampton 
and Vanniasinkam 2007) or, finally, (iii) gamma-irradiated or otherwise attenuated parasites 
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maintain metabolic functions, retain the capacity to invade mammalian cells, present 
antigens to the host’s immune system and elicit cellular immunity and cytokine responses in 
a highly similar way to natural infection (Hiramoto et al. 2002), and exogenous recombinant 
antigens do not. 
However, even though protection has been repeatedly demonstrated after immunization 
with whole-parasite vaccines, real concerns also exist regarding the use of this type of 
vaccines, in particular for uses other than veterinary immunization. The major fear is that 
attenuated parasites could revert to the pathogenic phenotype. For this reason, studies 
towards developing a human vaccine have focused on parasite extracts or recombinant 
technologies that use defined immunodominant antigens and delivery strategies. 
3.2 Immunogenic parasite extracts 
Identification and functional characterization of proteins of the tachyzoite stage of T. gondii 
has been the focus of extensive research, because antigens within this stage are presented to 
the immune system effectively during natural infection, forcing the parasite to enter (in less 
than two weeks) into the latent bradyzoite stage seeking for protection. This strategy results 
in physical parasite shielding by encystation and different, and much lower, antigen 
availability for the immune system.  
The soluble tachyzoite antigen extract (STAg) was the first protein blend identified as source of 
protective products, before wide-scale proteomic analyses were available (Denkers et al. 1993; 
Yap et al. 1998). Protection with STAg is only partial, even when the very efficient CpG 
oligodeoxynucleotides are used as adjuvants (Yin et al. 2007). Similar partial protection was 
also induced by the T. gondii sonicate of tachyzoites (TSo), even when mixed with cholera toxin 
(CT, a mucosal adjuvant) for oral administration (Bourguin et al. 1991; Bourguin et al. 1993). 
One of the reasons why immunogenic parasite extracts render non-protective immunity 
may be the diversification of immune responses amongst all the different antigens 
(immunodominant or not) present in those extracts. Additionally, the extraction process 
(in the case of STAg) may have eliminated some of the innate immunity activators, 
namely TLR agonists, present in the whole parasite. Current proteomic analyses (high-
throughput 2-dimensional electrophoresis combined with mass spectrometry) have 
identified nine novel vaccine candidates within STAg (Ma et al. 2009) and we should see 
some of these promising antigens being tested in vivo as recombinant subunit or 
vectorised vaccines in the near future. 
3.3 Individual antigens identified and used as subunit vaccines 
Three major particularities characterize the difficulties found in the development of 
recombinant vaccines against toxoplasmosis; these are: (i) T. gondii is an unicellular 
protozoan parasite formed by thousands of different proteins, glycoproteins, lipoproteins, 
and other types of molecules that can become feasible candidate antigens for a vaccine, (ii) 
the parasite evolves into several different stages during its life cycle, with some of those 
stages (cysts) particularly protected against the action of the immune system and, in 
addition, the antigens of one stage may not be effective vaccines for subsequent stages, and 
(iii) numerous strains of the parasite coexist in nature, most of them with significant 
differences in antigenic sequences, pathogenicity and physiological behavior within the 
host. Thus, protection induced against one strain may not be either cross-reactive or 
sufficient to prevent infection by other strain(s).  
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Apprehension in using attenuated whole parasites for human (and in many countries also 
animal) vaccination has lead research´s efforts to the development of safer vaccines by 
means of the identification and subsequent experimental administration of individual 
antigens. In principle, for an efficient immunization against T. gondii, the best antigens to 
use in vaccines should be those that are excreted/secreted (ESA) from the parasite stages 
that invade the host, since those have been reported as the most relevant targets of immune 
responses during natural infection, which, in contrast to what is seen in other diseases, 
controls the parasite´s ability to spread and multiply.  
The surface of the tachyzoite stage was the initial source of antigens tested as vaccines 
because of its accessibility. The abundant surface antigen 1 (SAG-1) was the initial and most 
widely studied tachyzoite antigen. Multiple other antigens (see figure 2) of the tachyzoite 
and bradyzoite stages of the parasite subsequently entered the vaccine development 
pipeline, and even sporozoite-specific antigens have recently begun to be identified in mice 
and humans (Hill et al. 2011). The use of all these antigens has been carefully reviewed by 
Jongert et al. (Jongert et al. 2009).  
In brief, up-to-date a few bradyzoite antigens, such as the abundant BAG-1, BRAD-1, CST-1, 
SAG4A, SRS-9, BSR-4, or the bradyzoite/tachyzoite expressed protein MAG-1 and, 
innumerable tachyzoite antigens, including surface antigens (SAGs), dense granule (GRAs), 
rhoptries (ROPs) and microneme (MICs) antigens have been identified and used as vaccine 
candidates with relative success and mostly in small experimental animal models.  
In humans, major T-cell antigens have yet to be identified (Boothroyd 2009) although recent 
tests using predicted CD8 epitopes derived from the most relevant mouse antigens could 
identify several reactive peptides presented by HLA-A02, A03 and B07 human major 
histocompatibility complex (MHC) molecules (Tan et al. 2010; Cong et al. 2011). Candidate 
proteins include 2 surface antigens (SAG1, and SUSA1, a surface marker specific to the slow-
growing, bradyzoite form of T. gondii) and 7 secreted proteins (GRA2, GRA3, GRA6, GRA7, 
ROP2, ROP16, ROP18).  
Recombinant proteins were the first and most obvious tools to induce immunity against T. 
gondii and antigens produced in bacteria or yeast cells were the first finely characterized 
molecules inoculated into experimental animals (Jongert et al. 2009). However, immunization 
with pure proteins did not show much success in terms of induction of protective immunity. 
Synthetic peptides encompassing antigenic epitopes were also tested as vaccine candidates 
(Duquesne et al. 1991), but with the same unfortunate fate. New combinations of 
antigens/adjuvants (specially the new generation of innate-stimulating adjuvants) aiming at 
inducing more adequate and stronger Th1/CTL responses are the paths to follow in order to 
improve the results obtained to date with these types of experimental vaccines.  
3.4 Genetic vaccines: DNA molecules and live vectors 
Proteins are excellent inducers of antibodies, but have some difficulties to induce high levels 
of T lymphocytes. Genetic vaccines, on the contrary, are highly efficient to induce antigen-
specific T lymphocytes. This group of vaccines represents a number of novel technologies 
that involve direct delivery of genes encoding antigens of interest to host cells, which then 
serve as antigen factories and immune-related processing plants for the resulting products. 
The intracellular presence of these products facilitates further induction of antigen-specific 
cellular immune responses by means of the easier antigen presentation in association with 
MHC class I molecules, which efficiently primes CD8+ T lymphocyte responses. These novel 
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vaccine technologies have therefore being used in clinical trials against a variety of 
pathogens for which this cellular immune profile renders protection (Barouch 2006). 
Immunization with DNA vaccines (almost exclusively bacterial plasmids because of the 
easy construction and multiplication, see Table 1) has traditionally been the first choice for 
experimental genetic vaccination against toxoplasmosis (Jongert et al. 2009). However, 
despite their successful application in many preclinical disease models, one of the most 
significant hurdles of DNA vaccine development has been transferring the success of 
inducing protective immunity in small animal models to larger animal models. The low 
potency of DNA vaccines in primates has so far precluded the development of most human 
health programs beyond Phase I clinical trials (Ulmer et al. 2006; Abdulhaqq and Weiner 
2008). The reasons for the failure of DNA vaccines to induce potent immune responses in 
humans have not yet been elucidated. However, it is reasonable to assume that the low 
levels of overall antigen production, the inefficient cellular delivery of DNA plasmids and 
the insufficient stimulation of the innate immune system may be the major causes 
responsible for the lack of efficiency (Ulmer et al. 2006). 
 
 
Abbreviations: p, plasmid; im, intramuscular; ip, intraperitoneal; sc, subcutaneous; in, intranasal; pSCA, 
suicidal vector based on the SFV replicon; T-ME, SAG1238–256, SAG1281–320, GRA1170–193, GRA4331–345, 
GRA4229–245, GRA2171–185; EC2, MIC2-MIC3-SAG1; EC3, GRA3-GRA7-M2AP; CTA2/B, Cholera toxin A2 
and B subunits. 
Table 1. Major DNA vaccine candidates recently developed and tested against T. gondii infection 
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In order to increase the immunogenicity of DNA vaccines in large animal models, various 
methods have been tested including: (i) improvements in the design of the plasmid, e.g. by 
adding antigen-ubiquitination signals for improved immunoproteasome degradation and 
antigen presentation (Ishii et al. 2006), (ii) delivering multiple antigens at the same time 
(Beghetto et al. 2005; Mevelec et al. 2005; Jongert et al. 2007; Xue et al. 2008; Qu et al. 2009; 
Wang et al. 2009; Hoseinian Khosroshahi et al. 2011), (iii) using chemical adjuvants or 
immunomodulatory molecules formulated into microparticles or liposomes (van Drunen 
Littel-van den Hurk et al. 2004; Greenland and Letvin 2007), and (iv) using plasmid 
molecules as part of prime-boost immunization regimes (Doria-Rose and Haigwood 2003; 
Dunachie and Hill 2003; Dondji et al. 2005; Shang et al. 2009). However, at present, the low 
immunogenicity of DNA vaccines has forced researchers to find alternative immunization 
vectors, and recombinant bacterial or viral vectors, which carry and express DNA sequences 
into the host organisms more efficiently, have gradually substituted bacterial plasmids for 
experimental vaccination studies.  
The use of bacteria as vehicles for genetic vaccination is an attractive and simple idea that 
derives from a number of intrinsic properties of the system. Live bacteria that contain 
recombinant plasmids encoding heterologous antigens of other pathogens have the 
potential of being oral delivery vectors for DNA vaccines in animal industry (Grillot-
Courvalin et al. 1999; Grillot-Courvalin et al. 2002). In Table 2. we show two studies 
conducted by Qu et al. in which ICR mice were orally immunized with DNA vaccines 
encoding SAG1 and/or MIC3 antigens delivered by an attenuated S. typhimurium strain 
(Dam− and PhoP−) at different doses, and challenged with 500 tachyzoites of T. gondii RH 
strain. Those studies show that oral administration of the attenuated bacteria could induce 
humoral and cellular immune responses, although they just elicited partial protection of 
animals (a maximum of 20% improvement in survival rate). Thus, new vectors and 
constructs have to be tested to consider this methodology as an applicable option. 
 
 
Abbreviations: p, plasmid; im, intramuscular; ip, intraperitoneal; sc, subcutaneous; in, intranasal; rPRV: 
recombinant pseudorabies virus; BV-G: recombinant baculovirus; rFLU: recombinant influenza A; rAd: 
recombinant adenovirus. 
Table 2. Selected examples of live attenuated vectors expressing Toxoplasma gondii antigens 
currently in tests.  
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Viral vectors exhibit many advantages for the development of a vaccine against 
toxoplasmosis. In summary, viral vectors express foreign antigens directly inside host cells 
very efficiently; as a result they present antigen fragments in association with MHC 
molecules more proficiently and, subsequently, they better stimulate the required anti-
toxoplasma T cell responses (Th1 and CTL) because they act as natural adjuvants and 
stimulate intracellular innate immunity receptors. In addition, they can be administrated 
through the natural route of infection, such as via nasal mucosa, and they are able to induce 
effective and long lasting immune responses. 
Our group has tested adenoviruses and influenza viruses as feasible vaccine vectors against 
toxoplasmosis (Caetano et al. 2006; Machado et al. 2010; Mendes et al. 2011) and they have 
shown significant improvement in comparison with naked plasmid vaccines. For those studies 
we have focused on possible formulations and immunization protocols using T. gondii surface 
antigens (SAGs). These molecules are involved in host cell attachment and invasion, and their 
sequences are conserved among different strains of T. gondii, sharing a high degree of 
homology even between type I (pathogenic and lethal in mice) and type II/III strains 
(cystogenic). However, these favorable traits do not ensure that these antigens will end up 
displaying sufficient protective capacities, but the proofs-of-principle obtained with their use 
will surely be maintained for any other antigens that display better protective properties.  
In Caetano et al. (Caetano et al. 2006), we generated three recombinant adenoviruses encoding 
genetically modified SAG1, SAG2 and SAG3, without the 3’-end GPI anchoring motifs to 
ensure secretion and subsequent induction of combined Th/CTL immune responses. BALB/c 
mice received rAd/SAG1, rAd/SAG2, rAd/SAG3, or a combination of the three viruses 
(rAdMIX) and were challenged with 100 live tachyzoites of the T. gondii RH strain or with 20 
cysts of the P-Br strain. Adenovirus immunization elicited potent antibody responses against 
each protein and displayed a significant bias toward a Th1 profile. When comparing the three 
recombinant viruses, rAd/SAG2 was the most efficient in eliciting antigen-specific antibodies. 
A significant reduction in cysts loads in the brain was observed in animals challenged with the 
P-Br strain. Vaccination with a mixture of all viruses promoted the highest level of inhibition 
of cyst formation, about 80%. However, no protection was observed against tachyzoites of the 
highly virulent RH strain (Caetano et al. 2006).  
In the study by Machado et al. (2010), we generated a recombinant Influenza A vector 
encoding SAG2 of T. gondii and explored an original heterologous prime-boost immunization 
protocol using influenza virus (rFLU/SAG2) and a recombinant adenovirus (rAd/SAG2). 
Influenza A viruses are promising but currently under-explored vectors, which display some 
advantageous features to be used as live recombinant vaccines, such as the ability to infect and 
activate antigen presenting cells as well as to present high immunogenicity at mucosal and 
systemic levels (Rocha et al. 2004; Machado et al. 2010). BALB/c mice primed with an 
intranasal rFLU/SAG2 dose and boosted with a subcutaneous rAd/SAG2 dose elicited both 
humoral and cellular immune responses specific for SAG2. Moreover, when immunized 
animals were challenged with the cystogenic P-Br strain of T. gondii, they displayed up to 85% 
of reduction in parasite burden. These results demonstrate the potential use of recombinant 
influenza and adenoviruses in vaccination protocols to protect against oral challenge with T. 
gondii (Machado et al. 2010), although there is room for improvement.  
Literature shows that, for other diseases, there is a good reproducibility of results when 
transferring experimental results obtained by immunization with some viral vectors (in 
particular adenoviruses) from small experimental animals to larger animal models or 
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humans. We expect this to be also true for the experimental vaccines generated against 
toxoplasmosis, so that we can see some encouraging results in the near future. 
4. Conclusion 
Recombinant subunit vaccines (proteins in adjuvants, DNA vaccines and recombinant live 
vectors) are the present trends for the development of a vaccine against Toxoplasmosis. A 
myriad of parasite antigens have been described and researchers are testing them in many 
animal models of the disease. It is our belief that, more than the description of new parasite 
antigens that could be used in a final vaccine formulation, one of the major issues for the 
next future is to develop and test highly antigenic formulations using currently known 
antigens. Developing this type of formulations requires a deep knowledge of the immune 
system’s antigen processing and presentation pathways, proficiency in the use of molecular 
biology techniques to adapt the parasite antigen sequences to enter those pathways, and 
using the new generation of adjuvants and delivery vectors in a manner that can best 
stimulate the pretended anti-parasite Th1 cellular (and probably humoral) immune 
responses. The options and combinations are so broad, and yet untested, that several years 
of research will be needed before we can decide which combination will be more adequate 
[antigen(s) + adjuvant(s) + vector(s)] or what will be the most efficient immunization 
protocol (single dose, multiple dose, homologous or heterologous prime-boost, etc.).  
Finally, we would like to call attention to the fact that a possible result of the 
immunization/protection tests may actually be the achievement of a cost-effective vaccine 
that may be suitable for large-scale production and use. Then, one key question will arise 
for the future, regarding the correct use of that vaccine. In principle, the vaccine should be 
applied to animals, because preventing oocyst shedding by cats and tissue cyst formation 
in meat-producing animals should have great impact on both environmental 
contamination and public health. But this intervention could pose a risk because of the 
loss of herd immunity against the parasite and the resurgence of a different profile of 
Toxoplasma-related pathologies because of the primo-infection of non-vaccinated adults 
traveling to other countries or regions instead of kids or young adults being infected at its 
home places. To solve this, a possibility would be the universal vaccination of all children 
against toxoplasmosis, although this might end up being not feasible in practice or even 
might not be considered as a priority. Researchers should include these topics amongst 
those to be discussed in the forthcoming years within the field of vaccine development 
against toxoplasmosis. 
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